MA51288B1 - Analogues d'incrétine et leurs utilisations - Google Patents

Analogues d'incrétine et leurs utilisations

Info

Publication number
MA51288B1
MA51288B1 MA51288A MA51288A MA51288B1 MA 51288 B1 MA51288 B1 MA 51288B1 MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A MA 51288 B1 MA51288 B1 MA 51288B1
Authority
MA
Morocco
Prior art keywords
activity
incretin
receptors
incretin analogs
analogues
Prior art date
Application number
MA51288A
Other languages
English (en)
Other versions
MA51288A (fr
Inventor
Jorge Alsina-Fernandez
Lili Guo
Tamer Coskun
Hongchang Qu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA51288A publication Critical patent/MA51288A/fr
Publication of MA51288B1 publication Critical patent/MA51288B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)

Abstract

L'invention concerne des analogues d'incrétine qui ont une activité au niveau de chacun des récepteurs de GIP, GLP-1 et glucagon. Les analogues d'incrétine ont des caractéristiques structurales conduisant à une activité équilibrée et une durée d'action prolongée à chacun de ces récepteurs. L'invention concerne également des procédés de traitement de maladies telles que le diabète sucré, la dyslipidémie, la stéatose hépatique, le syndrome métabolique, la stéatohépatite non alcoolique et l'obésité.
MA51288A 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations MA51288B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21
PCT/US2018/065663 WO2019125938A1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations
EP18830618.7A EP3727426B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Publications (2)

Publication Number Publication Date
MA51288A MA51288A (fr) 2021-03-31
MA51288B1 true MA51288B1 (fr) 2026-02-27

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51288A MA51288B1 (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Country Status (37)

Country Link
US (4) US11542313B2 (fr)
EP (2) EP3727426B1 (fr)
JP (3) JP6961838B2 (fr)
KR (2) KR102622642B1 (fr)
CN (1) CN111491658B (fr)
AR (1) AR113486A1 (fr)
AU (1) AU2018388962B2 (fr)
BR (1) BR112020010244A2 (fr)
CA (1) CA3084005C (fr)
CL (1) CL2020001635A1 (fr)
CO (1) CO2020006255A2 (fr)
CR (1) CR20200255A (fr)
DK (1) DK3727426T3 (fr)
DO (1) DOP2020000123A (fr)
EA (1) EA202091290A1 (fr)
EC (1) ECSP20032650A (fr)
ES (1) ES3061179T3 (fr)
FI (1) FI3727426T3 (fr)
HR (1) HRP20260186T1 (fr)
IL (2) IL275468B2 (fr)
JO (1) JOP20200137B1 (fr)
LT (1) LT3727426T (fr)
MA (1) MA51288B1 (fr)
MD (1) MD3727426T2 (fr)
MX (2) MX2020006548A (fr)
MY (1) MY199143A (fr)
PE (2) PE20251598A1 (fr)
PH (1) PH12020551025A1 (fr)
PL (1) PL3727426T3 (fr)
PT (1) PT3727426T (fr)
RS (1) RS67748B1 (fr)
SG (1) SG11202005606VA (fr)
SI (1) SI3727426T1 (fr)
SM (1) SMT202600216T1 (fr)
TW (3) TWI912614B (fr)
UA (1) UA129012C2 (fr)
WO (1) WO2019125938A1 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
US12257287B2 (en) * 2018-11-12 2025-03-25 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Glucagon-derived peptide and use thereof
WO2021034815A1 (fr) * 2019-08-19 2021-02-25 Eli Lilly And Company Procédés de fabrication d'analogues d'incrétine
CN122520749A (zh) * 2019-12-03 2026-08-07 安泰博医药 优化的gip肽类似物
AR120714A1 (es) 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
IL296592A (en) * 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co Qd dosing of gip receptor agonist peptide compounds and uses thereof
WO2022090447A1 (fr) 2020-10-30 2022-05-05 Novo Nordisk A/S Agonistes triples du récepteur de glp-1, gip et glucagon
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TW202423476A (zh) 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
CA3219647A1 (fr) * 2021-05-26 2022-12-01 The United Bio-Technology (Hengqin) Co., Ltd. Multiagonistes et utilisation connexe
WO2022268029A1 (fr) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Agoniste triple pour récepteurs glp-1, gcg et gip
AU2022298662B2 (en) 2021-06-23 2025-06-05 Eli Lilly And Company An incretin analog for use in glycemic control and weight management
CA3231953A1 (fr) 2021-09-15 2023-03-23 Brian Lian Compositions et methodes de traitement de troubles metaboliques et hepatiques
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
KR20240099485A (ko) * 2021-11-19 2024-06-28 메드샤인 디스커버리 아이엔씨. 스테이플화 펩타이드 및 이의 용도
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
KR20250057847A (ko) 2022-08-29 2025-04-29 일라이 릴리 앤드 캄파니 경구 전달용 조성물
CN117417411B (zh) * 2022-09-28 2025-08-29 广东东阳光药业股份有限公司 Glp-1/gcg/gip三受体激动剂及其用途
WO2024077149A2 (fr) 2022-10-05 2024-04-11 Eli Lilly And Company Peptides pour la synthèse d'incrétine
EP4622998A2 (fr) * 2022-11-21 2025-10-01 Eli Lilly and Company Procédé de préparation d'un double agoniste gip/glp1
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
AU2024215381A1 (en) 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
CN118684758A (zh) * 2023-03-23 2024-09-24 上海民为生物技术有限公司 肠促胰岛素类似物及其应用
WO2024213022A1 (fr) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 Analogues d'incrétine et leur procédé de préparation, et utilisation
EP4724472A2 (fr) * 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Nouveaux agonistes du récepteur double glp-1/gip et glp-1/gcg
AU2024305247A1 (en) 2023-06-15 2025-12-11 Novo Nordisk A/S Pharmaceutical formulations of an amylin receptor agonist and a glp-1 receptor agonist comprising a cyclodextrin
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法
EP4745153A1 (fr) 2023-07-14 2026-05-20 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triagoniste des récepteurs glp-1, gip et gcg et son utilisation
CN122094977A (zh) * 2023-10-26 2026-05-26 齐鲁制药有限公司 具有多重激动活性的多肽及其应用
CN120349393A (zh) * 2023-11-06 2025-07-22 成都奥达生物科技有限公司 一种三激动剂化合物
WO2025162423A1 (fr) * 2024-02-02 2025-08-07 杭州先为达生物科技股份有限公司 Triagoniste pour glp-1r, gipr et gcgr
TW202620038A (zh) * 2024-06-21 2026-05-16 美商紐羅克里生物科學有限公司 經化學修飾之肽及其用途
WO2025264809A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
WO2025264785A1 (fr) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Peptides chimiquement modifiés et leur utilisation
CN119978101B (zh) * 2024-07-30 2025-10-10 四川普康药业有限公司 多肽化合物及其应用
WO2026059846A1 (fr) 2024-09-13 2026-03-19 Eli Lilly And Company Timbre à micro-aiguilles solubles pour administration transdermique d'un peptide
TW202620036A (zh) 2024-09-27 2026-05-16 美商卡默療法股份有限公司 肽酪胺酸－酪胺酸（ｐｙｙ）類似物及ｇｌｐ－１ｒ促效劑之組合療法
WO2026076425A1 (fr) 2024-10-04 2026-04-09 Biodrive, Inc. Plate-forme de bioadministration orale
WO2026125286A1 (fr) * 2024-12-09 2026-06-18 Inventiva Combinaisons comprenant du lanifibranor et un agoniste triple des récepteurs glp-1/gip/glucagon destinées à être utilisées dans le traitement des maladies du foie
WO2026125238A1 (fr) 2024-12-10 2026-06-18 Camurus Ab Compositions et leurs méthodes d'utilisation
GB202418172D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
GB202418179D0 (en) 2024-12-11 2025-01-22 Algipharma As Compositions and methods
WO2026153399A1 (fr) * 2025-01-15 2026-07-23 江苏恒瑞医药股份有限公司 Composition pharmaceutique
CN119823233A (zh) * 2025-03-18 2025-04-15 杭州思诺达医药科技有限责任公司 瑞他鲁肽的合成方法及瑞他鲁肽
CN120189527B (zh) * 2025-05-27 2026-04-03 广州富肽生物有限公司 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途
CN120623312B (zh) * 2025-06-26 2026-01-23 乐普健糖药业(重庆)有限公司 Glp-1、gip、gcg三重受体激动剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2558842T3 (es) * 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
US8779103B2 (en) 2009-03-27 2014-07-15 Glaxo Group Limited Drug fusions and conjugates
WO2011088837A1 (fr) * 2010-01-20 2011-07-28 Zealand Pharma A/S Traitement d'états pathologiques cardiaques
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
WO2012153196A2 (fr) * 2011-05-10 2012-11-15 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (fr) * 2013-11-06 2022-05-03 Zealand Pharma A/S Composes agonistes doubles de gip et glp-1 et procedes associes
AR103242A1 (es) * 2015-01-09 2017-04-26 Lilly Co Eli Compuestos co-agonistas de gip y glp-1
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TWI783244B (zh) * 2015-06-22 2022-11-11 美商美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
JP6712323B2 (ja) * 2015-12-31 2020-06-17 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ−１及びｇｉｐ受容体のすべてに活性を有する三重活性体
EP3217027A1 (fr) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Élement de revetement large destine a entourer une tige d'ancrage
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) * 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
AU2019309798A1 (en) * 2018-07-23 2021-02-11 Eli Lilly And Company Method of using a GIP/GLP1 co-agonist for diabetes
ES3068975T3 (en) * 2018-07-23 2026-06-03 Lilly Co Eli Gip/glp1 co-agonist compounds
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
AR120714A1 (es) * 2019-12-18 2022-03-09 Lilly Co Eli Análogos de incretina y sus usos
CA3165430A1 (fr) * 2020-01-23 2021-07-29 Jorge Alsina-Fernandez Composes co-agonistes de gip/glp1
AU2024215381A1 (en) * 2023-01-31 2025-09-18 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof

Also Published As

Publication number Publication date
FI3727426T3 (fi) 2026-02-04
UA129012C2 (uk) 2024-12-25
EP4691555A2 (fr) 2026-02-11
ES3061179T3 (en) 2026-03-31
JP6961838B2 (ja) 2021-11-05
WO2019125938A1 (fr) 2019-06-27
IL275468B1 (en) 2026-01-01
MY199143A (en) 2023-10-17
JOP20200137B1 (ar) 2024-04-18
BR112020010244A2 (pt) 2020-10-13
PE20210162A1 (es) 2021-01-26
IL325353A (en) 2026-02-01
JP2022033724A (ja) 2022-03-02
IL275468B2 (en) 2026-05-01
KR102622642B1 (ko) 2024-01-10
PT3727426T (pt) 2026-02-03
JP7658877B2 (ja) 2025-04-08
CO2020006255A2 (es) 2020-05-29
PL3727426T3 (pl) 2026-03-16
US12365716B2 (en) 2025-07-22
CA3084005A1 (fr) 2019-06-27
TW201938188A (zh) 2019-10-01
TW202415675A (zh) 2024-04-16
SG11202005606VA (en) 2020-07-29
CL2020001635A1 (es) 2020-10-16
KR102444783B1 (ko) 2022-09-19
US20230203121A1 (en) 2023-06-29
KR20200088419A (ko) 2020-07-22
RS67748B1 (sr) 2026-03-31
US20250313605A1 (en) 2025-10-09
KR20220133304A (ko) 2022-10-04
CN111491658B (zh) 2024-04-26
AU2018388962B2 (en) 2020-11-19
US20250059251A1 (en) 2025-02-20
MX2020006548A (es) 2020-09-14
LT3727426T (lt) 2026-02-10
US11542313B2 (en) 2023-01-03
TWI912614B (zh) 2026-01-21
AR113486A1 (es) 2020-05-06
EP3727426A1 (fr) 2020-10-28
US12371465B2 (en) 2025-07-29
EP4691555A3 (fr) 2026-04-22
IL275468A (en) 2020-08-31
SMT202600216T1 (it) 2026-07-16
JOP20200137A1 (ar) 2022-10-30
JP2021506955A (ja) 2021-02-22
ECSP20032650A (es) 2020-07-31
TWI809515B (zh) 2023-07-21
PE20251598A1 (es) 2025-06-16
PH12020551025A1 (en) 2021-09-06
MD3727426T2 (ro) 2026-04-30
EP3727426B1 (fr) 2025-11-26
US20200331980A1 (en) 2020-10-22
TW202202518A (zh) 2022-01-16
CR20200255A (es) 2020-07-12
DK3727426T3 (da) 2026-02-02
HRP20260186T1 (hr) 2026-03-27
EA202091290A1 (ru) 2020-09-10
TWI744579B (zh) 2021-11-01
AU2018388962A1 (en) 2020-06-04
JP2025093970A (ja) 2025-06-24
NZ765277A (en) 2024-08-30
DOP2020000123A (es) 2020-08-31
MA51288A (fr) 2021-03-31
CA3084005C (fr) 2024-01-02
SI3727426T1 (sl) 2026-04-30
CN111491658A (zh) 2020-08-04
MX2024010201A (es) 2024-08-26

Similar Documents

Publication Publication Date Title
MX2024010201A (es) Analogos de incretina y sus usos.
MX2025003745A (es) Analogos de incretina y sus usos
CR20220279A (es) Análogos de incretina y sus usos
MX382408B (es) Coagonistas de los receptores de glucagón y de glp-1.
PH12019501216A1 (en) New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists
MX2016004907A (es) Analogos del glucagon.
MY176022A (en) Acylated glucagon analogues
MX380322B (es) Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1).
MX2019006427A (es) Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip.
JOP20200231B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
MX2017012864A (es) Analogo acilado del glucagon.